LYNN HEALTH SCIENCE INSTITUTE IS LOOKING FOR PARTICIPANTS
PAID CLINICAL TRIAL
- 6 months
- 12-13 clinic visits
YOU MAY BE ELIGIBLE TO PARTICIPATE IF YOU MEET THE FOLLOWING CRITERIA:
- Have a diagnosis of Migraines
- 18 years of age and older
We are doing this study to learn more about the efficacy and safety of MEDI0618 (also known as ABBV-2002) in participants with frequent migraine headaches and also to better understand migraine headaches and associated health problems. MEDI0618 is being developed for the prevention of migraines. The goal of preventive
therapy is to reduce the frequency, duration, or severity of migraine attacks. Over the
past few years, therapies targeting the calcitonin gene-related peptide (CGRP) pathway, called aCGRP therapy, have been approved for prevention of migraine. However, it has been found that a considerable proportion of migraine patients do not benefit from current available preventive treatments, including aCGRP therapy.
Lynn Institute is a leader in introducing new medications to the market through our clinical trials program. Visit our Participation Information page for Frequently Asked Questions, to see current clinical trials listed, and to find out where each trial is being conducted.
Find out More About Our Participation Program
Participation Information